Pressemeddelelse fra ViroGates
The research coverage is governed by an agreement made between ViroGates and Västra Hamnen Corporate Finance. The analysis comprises an independent review of the Company, its products, markets and competitors as well as a financial scenario that constitutes the basis of an estimated justified market capitalization of ViroGates.
In its initiation coverage report, Västra Hamnen Corporate Finance AB concludes:
“Our DCF model suggests a fair value range for the stock price of DKK 68.00 – DKK 100.50 given our current view of the risk and including only the Acute Care market in our model. We see potential for further valuation upgrades when the company has overcome certain risks and when it gets closer to addressing other market segments.”
The initiation coverage report is available at Västra Hamnen’s and at ViroGates’ investor website
For additional information, please contact
CEO Jakob Knudsen
Tel. (+45) 2226 1355, Email:ViroGates A/S – www.virogates.com
Certified Advisor
Västra Hamnen Corporate Finance
Per Lönn
Tel. (+46) 40 200 250, Email:
Læs hele pressemeddelelsen på Via Ritzau her: https://via.ritzau.dk/pressemeddelelse/vastra-hamnen-corporate-finance-initiates-coverage-of-virogates?releaseId=13587097
